Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic implantable cardiac monitors

This article was originally published in The Gray Sheet

Executive Summary

Medtronic's Reveal DX next-generation implantable cardiac monitor will debut in the U.S. the week of Dec. 17 following 510(k) clearance Nov. 21, the firm announces Dec. 12. Building on the firm's earlier generation Reveal insertable loop recorders, the advanced Reveal DX has enhanced ECG and trend data capabilities, and can monitor the heart continuously for up to three years instead of just 14 months with the old system, the company explains. Placed just under the skin in the chest area, Reveal DX has no lead wires and helps physicians to diagnose whether symptoms such as dizziness and fainting are caused by cardiovascular problems, the firm says. Medtronic's similar Reveal XT, also cleared by FDA Nov. 21, is marketed in Europe for atrial fibrillation monitoring and is expected to debut in the United States at a later date

You may also be interested in...



COVID-19 Lockdown: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.

Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.

Kansas City TCM Firm Persists With COVID-19 Claims Following US Regulators' Warning

Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.

UsernamePublicRestriction

Register

MT025602

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel